Observations that make me uncomfortable, page-8

That's all good and well, except who named in the above improves PFS by 3 months over FOLFIRI?

I think everyone is missing the point that most systematic chemo drugs do not specifically target cancer cells. The value of HyACT isn't in treating mCRC, it's in wrapping (almost) all the systematics

i.e. If Pfizer has a drug that beats FOLFIRI by 3 months, I'd want to wrap it and beat FOLFIRI by 6 months and ensure absolute market dominance. So I'd take ACL out if Phase 3 proves that it works